SPL 850
Alternative Names: SPL-850Latest Information Update: 26 Oct 2023
At a glance
- Originator SAJE Pharma
- Class Anti-inflammatories; Antihyperglycaemics; Eye disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Glutathione-independent formaldehyde dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Crohn's disease; Diabetes mellitus; Eye disorders; Inflammation; Stroke
Most Recent Events
- 31 Dec 2020 Preclinical trials in Crohn's disease in USA (PO) (SAJE Pharma pipeline; September 2023)
- 31 Dec 2020 Preclinical trials in Diabetes mellitus in USA (PO) (SAJE Pharma pipeline; September 2023)
- 31 Dec 2020 Preclinical trials in Eye disorders in USA (Topical) (SAJE Pharma pipeline; September 2023)